Previous close | 10.48 |
Open | 10.65 |
Bid | 10.58 x 100 |
Ask | 10.88 x 100 |
Day's range | 10.11 - 10.96 |
52-week range | 8.25 - 27.03 |
Volume | |
Avg. volume | 132,475 |
Market cap | 74.972M |
Beta (5Y monthly) | 1.57 |
PE ratio (TTM) | N/A |
EPS (TTM) | -332.12 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 33.00 |
DURHAM, N.C., May 01, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B (HBV) during a poster presentation at the European Association
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
DURHAM, N.C., April 16, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration. Precision uses its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated g